GM PHARMA Named “Leader of the Year” Once Again in 2025
The international pharmaceutical company GM PHARMA has once again become the winner of the joint award of the Swiss Rating Association and the National Business Ratings Union – “Leader of the Year 2025.” This achievement highlights the company’s dynamic and sustainable development, reflected in its consistently leading position in Georgia’s pharmaceutical market.
Among pharmaceutical companies in Georgia, GM PHARMA received the prestigious “Leader of the Year” award, based on key financial and economic indicators such as profit/loss, turnover, average monthly employee salary, personnel expenses and number of employees.
It is noteworthy that GM PHARMA has maintained its “Leader of the Year” status since 2017 according to the criteria set by the Swiss Rating Association. This award is the only business recognition event of international status held in Georgia. The nomination of companies is determined through a dual evaluation system, rating assessments and a direct survey method. The ranking is based on public data from the National Statistics Office of Georgia (GeoStat), using national classification standards and financial-economic indicators in accordance with the methodology approved by the National Business Ratings Union.
For GM PHARMA, the international rating award “Leader of the Year 2025” holds special significance, as the company is celebrating its 25th anniversary this year. This recognition represents not only an evaluation of its business achievements but also a symbolic acknowledgment of the continuous path of growth and development that the company has pursued with dedication and responsibility over the past quarter of a century.
The company emphasizes that maintaining its leadership status for many years is the result of a strategic vision and a consistent development policy. GM PHARMA’s goal has always been not only to build a strong business but also to create a pharmaceutical ecosystem grounded in international standards of quality, reliability and innovation.
The international pharmaceutical company GM PHARMA operates a manufacturing facility in Tbilisi, which is one of the leading pharmaceutical plant in the South Caucasus region. The enterprise is distinguished by a complete technological cycle for the production of solid dosage forms of medicines. A full technological cycle encompasses the entire process – from sourcing raw materials to the release of the final product, including dispensing, blending, granulation, tableting, tablet coating, capsule filling, bottle filling, sachet filling and blister and bottle packaging, quality control.
GM PHARMA’s medicines and food supplements manufactured in GMP-certified manufacturing plants in Western European countries (Germany, Greece, Spain, Switzerland, Italy, Sweden, Portugal) and in its own GMP-certified manufacturing plant in Georgia.
The company holds national and international certificates, permits and licenses required for pharmaceutical manufacturing: Good Manufacturing Practice – National GMP (Georgia), Good Manufacturing Practice – GMP PIC/S (International), Quality Management – ISO 9001:2015 and ISO 17025:2017/2018.
It is remarkable that, 25 years after its founding, GM PHARMA remains driven by an ambitious vision. Today, the company is focused on expanding its business horizons and building new international partnerships, with a strategic goal of entering and strengthening its presence across European, South-East Asian, South and Central American markets.
Since its founding, the company's mission and values have remained unchanged – based on scientific approaches and industry best practices, continuous improvement of quality and products, the production and supply medicines that improve and prolong patients’ lives.
GM PHARMA – serving those who need it most!